Reimbursement Information
Setting: Hospital Outpatient

About DOTAREM®:
DOTAREM is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.¹

IMPORTANT SAFETY INFORMATION¹

<table>
<thead>
<tr>
<th>WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.</td>
</tr>
<tr>
<td>• The risk for NSF appears highest among patients with:</td>
</tr>
<tr>
<td>– Chronic, severe kidney disease (GFR &lt; 30 mL/min/1.73m²), or</td>
</tr>
<tr>
<td>– Acute kidney injury.</td>
</tr>
<tr>
<td>• Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age &gt; 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.</td>
</tr>
<tr>
<td>• For patients at highest risk for NSF, do not exceed the recommended DOTAREM dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.</td>
</tr>
</tbody>
</table>

Important Safety Information continued onto the following pages.

Billing for DOTAREM:
DOTAREM (gadoterate meglumine), having received FDA approval for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues in adult and pediatric patients (including term neonates), has recently been assigned a distinct Healthcare Common Procedural Coding System (HCPCS) code, A9575, by the Centers for Medicare and Medicaid Services (CMS). A9575 should be used for all billing to all third-party payers, governmental and private in all patient settings. This code, effective January 1, 2014, was made available to all Medicare Administrative Contractors (MACs) and all major national and significant regional payers.
Setting: Hospital Outpatient

A9575 (HCPCS Code)*:

In order for payers to correctly reimburse HCPCS A9575 (Injection, gadoterate meglumine, 0.1 ml), providers must indicate the following in the electronic narrative (Item 19 or the descriptor field) of the Centers for Medicare and Medicaid Services (CMS) UB04 form:

- The name of the drug
- National Drug Code (NDC) number
- The total dosage (plus strength of dosage, if appropriate)
- The method of administration
- NDC unit of measure is mL

Revenue Codes:
The following possible revenue codes may be used as applicable:

- 255 (drugs incident to radiology services)
- 250 (General Pharmacy)
- 636 (drugs requiring detailed coding)

Medicare:

MRI contrast agents are not paid separately by Medicare in the hospital outpatient setting; payment is packaged into the procedure payment rate. Providers, however, should report/bill for contrast so that CMS can continue obtaining accurate cost and charge data necessary to set future reimbursement payments. A9575 reimbursement is bundled into the corresponding procedure APC payment.

Private/Commercial Payers:
Contrast reimbursement may be paid separately when contracted for separate payment with the payer and billed with a covered procedure. This varies from payer to payer. Providers, please check your contracts and/or contact private payers for further information, or call the DOTAREM® Reimbursement Support line.

For assistance, please contact DOTAREM Reimbursement Support at 1-855-368-2736, Monday–Friday, 7 am–7 pm ET.

*Reimbursement information provided is for illustrative purposes only and does not constitute legal advice. Information provided is gathered from third party sources and is subject to change without notice due to frequently changing laws, rules and regulations. Guerbet makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare or other third party payers as to the correct form of billing or the amount that will be paid to providers of service. The provider of service has the responsibility to determine medical necessity and to submit appropriate codes and charges for care provided. Please contact your local payers, reimbursement specialists and/or legal counsel for interpretation of coding, coverage, and payment policies. Guerbet does not promote the use of its products outside FDA-approved labeling.

For more information on Dotarem, please see Full Prescribing Information including Boxed Warning and Medication Guide.
INDICATIONS AND USAGE

• Consequences of gadolinium retention in the brain have not been established. Adverse events involving multiple organ systems have been reported with DOTAREM. These serious adverse reactions include but are not limited to: arrhythmia, cardiac arrest, respiratory arrest, pharyngeal edema, laryngospasm, bronchospasm, coma and convulsion.

WARNINGS AND PRECAUTIONS

• The risk for NSF appears highest among patients with:
  – Chronic, severe kidney disease (GFR < 30 mL/min/1.73 m²), or
  – Acute kidney injury.

• Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g., age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.

• For patients at highest risk for NSF, do not exceed the recommended DOTAREM dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.


Reimbursement Information